Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?

Recursion Pharma (RXRX) shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below both its 50-day and 200-day moving averages.RXRX Stock Underperforms the Industry, Sector & the S&P 500Image Source: Zacks Investment ResearchThe recent decline in Recursion Pharma's stock can be attributed to a combination of macroeconomic c ...